I+D de fármacos
GI-1606
![Foto de I+D de fármacos](/img/grupo.png)
![Foto de Uppsala University](/img/noimage_org.png)
Uppsala University
Upsala, SueciaPublicacións en colaboración con investigadores/as de Uppsala University (3)
2021
-
3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition
Journal of medicinal chemistry, Vol. 64, Núm. 1, pp. 458-480
2017
-
3-Oxopyridazin-5-yl-Chalcone Hybrids: Potent Antiplatelet Agents That Prevent Glycoprotein IIb/IIIa Activation
ChemistrySelect, Vol. 2, Núm. 17, pp. 4920-4933
-
Enantiospecific Recognition at the A2B Adenosine Receptor by Alkyl 2-Cyanoimino-4-substituted-6-methyl-1,2,3,4-tetrahydropyrimidine-5-carboxylates
Journal of Medicinal Chemistry, Vol. 60, Núm. 8, pp. 3372-3382